Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL

Sun Yat-sen University

Status: Enrolling

Conditions: Pediatric Cancer; Lymphoma, Non-Hodgkin; Rituximab

Study type: Observational

Funder types: Other

Identifiers

NCT03958916

SCCCG-BL/DLBCL-2017-001

Details and patient eligibility

About

The trial SCCCG-BL/DLBCL-2017 is a collaborative prospective, multicenters, non-randomized, observational, cohort clinical study with participating centers of the South China Children's Cancer Group-Non-Hodgkin lymphoma group(SCCCG-NHL). The aim of the study is to evaluate efficacy and safety of stratified treatment based on risk factors of childhood and adolescents Burkitt lymphoma(BL)/diffuse large B-cell lymphoma(DLBCL) patients in china.

Full description

Research purposes:

1. To investigate the efficacy and safety of SCCCG-BL/DLBCL-2017 in children with BL and DLBCL.
2. To investigate the effect of rituximab combined with chemotherapy on the survival rate of children with high-risk BL/DLBCL.
3. To investigate the effect of rituximab on immune function in children with high-risk BL/DLBCL.
4. To explore the correlation between MRD detection and the efficacy and survival of children with BL/DLBCL.
5. To explore the role of PET/CT in evaluating residual lesions in children after BL/DLBCL treatment.

Enrollment: 500 estimated patients

Sex: All

Ages: 1 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age < 18 years old
2. Pathologically confirmed Burkitt lymphoma or diffuse large B-cell lymphoma
3. Newly diagnosed patients
4. Informed consent of guardian of children patients

Exclusion criteria

1. Pathological components with follicular lymphoma
2. Immunodeficiency Second neoplasm